Antagonism of platelet-activating factor-induced increase in cytosolic free calcium concentration in human endothelial cells.

The effects of platelet-activating factor (PAF) antagonists on the agonist-induced increase in cytosolic free calcium concentration, [Ca2+]i, in human vascular endothelial cells grown in monolayer were investigated by a continuous superfusion technique using a calcium fluorescent probe, fura-2. PAF caused a small but dose-dependent increase in [Ca2+]i. Seven structurally dissimilar PAF antagonists dose-dependently suppressed the peak response, among which WEB 2086 was the most potent, followed by WEB 2170 greater than FR 900452 not equal to ONO 6240 greater than BN 52021 not equal to kadsurenone not equal to CV 3988. These antagonists except for CV 3988 were specific for PAF, since they had no effects on calcium mobilization induced by thrombin or histamine, while CV 3988 had a non-specific effect. PAF in the same range of concentration increased prostacyclin release from human endothelial cells. WEB 2086 also inhibited the PAF-induced prostacyclin release, while it had not effect on the release induced by histamine and thrombin. These results demonstrate the specificity and dose-response characteristics of PAF antagonists in cultured human endothelial cells and suggest that a PAF antagonist could be a valuable therapeutic agent in certain human diseases where PAF activation of endothelial cells may have a critical role.     

Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation.

1. The effects of the platelet activating factor (Paf) antagonists alprazolam, BN 52021, kadsurenone, L 652,731 and SRI 63119 have been studied on Paf-induced chemiluminescence (CL) of guinea-pig, C. parvum-activated peritoneal macrophages in vitro. 2. All antagonists produced a shift to the right in the dose-response curve to Paf (0.001-10 mumol l-1). Schild plots for BN 52021, L 652,731, kadsurenone and SRI 63119 were linear, but only for BN 52021 and kadsurenone did the mean slope not differ significantly from unity. Mean pA2 values for BN 52021 and kadsurenone were 6.60 +/- 0.05 and 6.41 +/- 0.14 (mean + s.e.mean) respectively. Calculation of IC50 values for all antagonists (at 0.1 mumol l-1 Paf) gave an order of potency: L 652731 greater than kadsurenone greater than or equal to BN 52021 greater than alprazolam greater than SRI 63119. 3. When individual pA2 values for BN 52021 and kadsurenone were plotted against the maximal CL response to Paf of cell suspensions in the absence of antagonist (reflecting the degree of activation of the macrophages by the C. parvum), it was found that the affinity of both antagonists for macrophage Paf receptors remained relatively constant irrespective of the activation state of the cells. 4. We conclude that activation of guinea-pig peritoneal macrophages does not account for the increased affinity for macrophage Paf receptors previously observed for kadsurenone. Kadsurenone and BN 52021 presumably bind to a site on Paf receptors which is not affected by the activation process, while alprazolam and SRI 63119 are non-specific antagonists. The reason for the difference between the competitive nature of kadsurenone and its structural analogue L 652,731 is unclear.     

Characteristics of the bradykinin-induced changes in intracellular calcium ion concentration of single bovine tracheal smooth muscle cells.

1. Single bovine tracheal smooth muscle (BTSM) cells were cultured and used to measure bradykinin-induced changes in [Ca2+]i by dynamic video imaging. 2. Bradykinin (10 pM-10 microM)-induced an increase in [Ca2+]i over basal levels (69 +/- 2 nM; n = 353) which was concentration-dependent (log EC50 = -8.7 M) in the presence of extracellular calcium ions (2 mM). The bradykinin B2 receptor antagonist, D-Arg[Hyp3,Thi5,8,D-Phe7]- bradykinin, produced a parallel shift to the right of the bradykinin concentration-response curve (log EC50 = -7.1 M and -5.8 M in the presence of 1 microM and 10 microM antagonist respectively) yielding an apparent KD of 26 nM. 3. In the absence of extracellular calcium ions (with 0.1 mM EGTA), bradykinin (10 pM-10 microM) produced a uniform increase in [Ca2+]i from a basal level of 33 +/- 2 nM (n = 140) to approximately 180 nM in BTSM cells indicating an 'all-or-nothing' release of intracellular calcium ions. In the presence of 10 microM D-Arg[Hyp3,Thi5,8,D-Phe7]-bradykinin no responses could be induced by bradykinin at concentrations below 100 nM. However, at 100 nM and 1 microM bradykinin there was no change in the uniform increase in [Ca2+]i in these cells previously observed. 4. In both the absence or presence of D-Arg[Hyp3,Thi5,8,D-Phe7]-bradykinin, there was a concentration-dependent increase in the percentage of cells responding to bradykinin (frequency) under calcium-rich or calcium-free conditions. Individual cells also demonstrated a difference in the sensitivity to any particular concentration of bradykinin.(ABSTRACT TRUNCATED AT 250 WORDS)     

Mechanisms of platelet activating factor-induced changes in sheep tracheal blood flow.

1. The effects of platelet activating factor (PAF) have been studied on the cervical tracheal vasculature and smooth muscle of anaesthetized sheep. 2. The predominant action of PAF (2 pmol-2nmol) was a dose-dependent fall in tracheal vascular resistance. The maximum fall in resistance was -41.6% (-38.5 to -44.7%, 95% confidence interval) and the ED50 was 17 pmol (12-28 pmol). Lyso-PAF (200 pmol) did not change vascular resistance. 3. PAF had no effect on tracheal smooth muscle tone assessed by measuring changes in the external diameter of the trachea. 4. The fall in vascular resistance produced with PAF was unaffected by the anti-asthma drug nedocromil sodium (1 mg, i.a.), the cyclo-oxygenase inhibitor indomethacin (5 mg kg-1, i.v.), the leukotriene receptor antagonist FPL55712 (2 mg kg-1, i.v.), or a combination of the histamine H1- and H2-antagonists mepyramine (2 mg kg-1, i.v.) with cimetidine (5 mg kg-1, i.v.). The PAF antagonist WEB 2086 (300 micrograms kg-1, i.v.) significantly reduced the vasodilatation produced by PAF (before, -40.8 +/- 4.2%; after -16.5 +/- 5.9%, P less than 0.05). 5. Thus in this model, PAF is a potent vasodilator of the tracheal circulation but has no action on tracheal smooth muscle. The vasodilatation is mediated by specific PAF receptors and is not due to the release of prostanoids, leukotrienes or histamine.     

Des-Arg9-bradykinin-induced increases in intracellular calcium ion concentration in single bovine tracheal smooth muscle cells.

1. Dynamic video imaging was used to measure the des-Arg9-bradykinin-induced changes in the intracellular free calcium ion concentration ([Ca2+]i) of single bovine tracheal smooth muscle (BTSM) cells. 2. In the presence of extracellular calcium ions, des-Arg9-bradykinin (1 nM-10 microM) produced a concentration-dependent increase in the [Ca2+]i over basal levels yielding an EC50 value of 316 nM. The percentage of cells responding to each concentration of des-Arg9-bradykinin also increased in a concentration-dependent manner (from 9% to 100%). 3. The bradykinin B2 receptor antagonist, D-Arg[Hyp3,Thi5,8,D-Phe7]-bradykinin (10 microM), was without effect on the calcium response of the cells when added 2 min prior to des-Arg9-bradykinin (100 nM). However, the B1 receptor antagonist, des-Arg9Leu8-bradykinin (10 microM), completely abolished the des-Arg9-bradykinin-induced response. 4. Under calcium-free conditions, des-Arg9-bradykinin induced an increase in [Ca2+]i at concentrations of 1 microM and 10 microM. The response to 10 microM des-Arg9-bradykinin was reduced by preincubation of either D-Arg[Hyp3, Thi5,8,D-Phe7]-bradykinin (10 microM) or des-Arg9Leu8-bradykinin (10 microM). 5. We conclude that bradykinin B1 receptors are expressed by cultured BTSM cells and mediate the des-Arg9-bradykinin-induced influx of calcium ions at low agonist concentrations (< 1 microM). At higher concentrations, des-Arg9-bradykinin (1 microM and 10 microM) can stimulate both B1 and B2 receptors to effect intracellular calcium release under calcium-free conditions.     

N-desethylamiodarone modulates intracellular calcium concentration in endothelial cells

The main in-vivo metabolite of amiodarone, N-desethylamiodarone (DEAM), possesses clinically relevant class-II antiarrhythmic and vasodilator activities. Vasodilation by DEAM is endothelium dependent and involves a sustained and biphasic increase in cytosolic free Ca2+ concentration ([Ca2+]i). The aims of this study were to explore the mechanisms mediating the DEAM-induced increase in [Ca2+]i in endothelial cells and to determine whether this increase in [Ca2+]i was associated with altered cell proliferation. Cultured bovine aortic endothelial cells were loaded with the Ca2+-sensitive fluorescent dye Fura-2/AM, and [Ca2+]i measured spectrofluorimetrically. DEAM increased [Ca2+]i concentration dependently (EC50 approximately 6 microM) both in the presence and absence of extracellular Ca2+. In the presence of extracellular Ca2+, the response of [Ca2+]i to DEAM (10 microM) consisted of an initial rise to a plateau followed by a second increase to micromolar levels. The initial plateau was reduced by the endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin (200 nM) and by the antioxidant ascorbic acid (100 microM). The initial rate of rise in [Ca2+]i was decreased by blocking mitochondrial Ca2+ release with cyclosporine A (1 microM). Under Ca2+-free conditions, the response of [Ca2+]i to DEAM (10 microM) was also biphasic, consisting of an initial transient peak and a second slow increase. When extracellular Ca2+ was restored, [Ca2+]i rose to micromolar concentrations. The initial peak was abolished by thapsigargin, but not altered by ascorbic acid or cyclosporine A. Both the second [Ca2+]i increase and that due to restoring extracellular Ca2+ were reduced by ascorbic acid but not affected by thapsigargin or cyclosporine A. The DEAM-induced generation of free radicals and sustained increase in [Ca2+]i might alter cell proliferation and endothelial cell proliferation was indeed concentration-dependently inhibited by DEAM (IC50 approximately 2.5 microM). In conclusion, the DEAM-induced [Ca2+]i increase in endothelial cells is due to Ca2+ influx from the extracellular space and to Ca2+ release from endoplasmic reticulum and mitochondria and involves enhanced generation of free radicals.     

小檗胺对培养的HeLa细胞内游离钙浓度的作用

AIM: To study the involvement of Ca2+ signaling and the effects of berbamine (Ber) on intracellular calcium concentration ([Ca2+]i) elevated in cultured HeLa cells. METHODS: [Ca2+]i was measured by confocal microscopy in single HeLa cell loaded with Fluo 3-AM. The change of [Ca2+]i was represented by fluorescent intensity (FI). RESULTS: (1) In the presence of extracellular Ca2+ 1.3 mmol.L-1, the resting level of FI was 186 +/- 44, n = 49 cells from all control experiments, and KCl, NE, caffeine, and calcimycin (Cal) all induced [Ca2+]i elevations in cultured HeLa cells. (2) The resting level of FI was not affected by pretreatment with Ber. The FI increased by KCl 60 mmol.L-1, NE 100 micromol.L-1, and Cal 30 micromol.L-1 were attenuated (P < 0.05 or P < 0.01), the slope and the time to peak of FI increase were decreased and prolonged. (3) In the absence of extracellular Ca2+, caffeine 80 mmol.L-1-induced [Ca2+]i mobilization was not inhibited by Ber 100 micromol.L-1 pretreatment. (4) These effects of Ber were similar to those of verapamil (Ver) 10 mumol.L-1. CONCLUSION: Although it was derived from cervical cancer, the HeLa cells which were belong to the nonexcitable cell possessed the similar biological properties with excitable cells, and Ca2+ also played a crucial role in signal transduction processes.     

Ethanol and platelet intracellular free calcium concentrations.

The effect of 0.8 g kg-1 absolute ethanol orally on platelet intracellular free calcium was assessed in a random order study in 24 normotensive subjects with an isocaloric control. Platelet calcium was measured 90 min and 12 h after treatment by the Quin 2 method. The study had 90% power of detecting a 16.5% change. After 90 min, breath ethanol was 37 +/- 9 micrograms 100 ml-1, blood pressure was unchanged and heart rate rose slightly. Platelet calcium was unchanged by ethanol after 90 min or 12 h.     

The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells.

1. Nitrendipine induces NO-release from coronary vascular endothelium presumably by activating endothelial NO-synthase. We have investigated whether this effect may be mediated by an influence on the intracellular calcium in endothelial cells. 2. Bovine aortic endothelial cells (BAEC) were incubated with Fura-2/AM (1 microM) for 30 min and Fura-2 fluorescence was measured at 510 nm in response to chopped excitation with both 340 and 380 nm. The ratio 340/380 nm (known to reflect changes in intracellular calcium) was calculated from these data. 3. Nitrendipine (0.1 to 100 microM) led to a significant, concentration-dependent, monophasic increase in [Ca2+]i in suspended BAEC by 11 +/- 2 nM (0.1 microM), 23 +/- 3 nM (1 microM), 34 +/- 4 nM (10 microM) and by 47 +/- 5 nM (100 microM) from a control levels of 118 +/- 10 nM. 4. This elevation of intracellular calcium was prevented by pretreatment of BAECs with gadolinium (100 microM) or by incubation with calcium free saline solution. In contrast, the application of 0.3 microM thapsigargin did not abolish the nitrendipine-induced calcium signal. In additional experiments it was shown that the nitrendipine-induced NO-release (as measured with the oxy-haemoglobin-method could also be inhibited by gadolinium and was absent in calcium-free solution. 5. Thus, nitrendipine elevates intracellular calcium in suspended BAECs in a concentration-dependent manner. This elevation is mainly due to a gadolinium-sensitive calcium influx from the extracellular space rather than a calcium release from intracellular stores.     

蛋白酪氨酸磷酸化在血小板激活因子诱导血小板信号传导中的调节 …

AIM: To study the role of protein tyrosine phosphorylation (PTP) in platelet activating factor (PAF)-induced platelet signal transduction cascade. METHODS: Washed rabbit platelets were used to test the inhibitory effect of genistein (Gen) on platelet aggregation and serotonin secretion. Intracellular Ca2+ ([Ca2+]i) and pH (pHi) were measured by a dual wavelength fluorophotometer with Fura 2-AM and BCECF-AM. PTP was determined with a specific anti-phosphotyrosine monoclonal antibody by Western blotting. RESULTS: Pretreatment with Gen (100 and 200 mumol.L-1) inhibited PAF (20 nmol.L-1)-stimulated platelet serotonin release by 23.7% +/- 2.0% and 41% +/- 8%, respectively. Similar inhibitory effects of Gen were observed on PAF-evoked increase of [Ca2+]i and intracellular alkalization. PAF also elicited a pronounced increase in PTP of several bands with M(r) 70,000, 60,000, 50,000, 42,000/40,000, and 34,000, which were suppressed markedly by Gen 200 and 400 mumol.L-1. Pretreatment with staurosporine (Sta) 20 nmol.L-1, BAPTA 200 mumol.L-1, and egtazic acid 2 mmol.L-1 to inhibit PKC activation, [Ca2+]i elevation, and Ca2+ influx respectively, also showed an inhibitory effects on the formation of PTP. CONCLUSION: PTP is involved in multiple signal transduction pathways induced by PAF, on which PKC activation and calcium mobilization play a regulatory role.     

Rise in intracellular calcium concentration elicited by isradipine in Gin-1 cells.

We performed experiments to examine whether isradipine (Isr), a calcium antagonist, would raise the intracellular calcium concentration ([Ca2+]i) in Gin-1 cells and, if so, to elucidate the mechanism of the [Ca2+]i rise. Gin-1 cells, which are human normal gingival fibroblasts were used as the material. The [Ca2+]i was measured with the Ca2+-sensitive fluorescent dye fura-2/AM. Changes in the fluorescence intensity of fura-2 in the cells were recorded with a video-imaging analysis system. Isr concentration-dependently raised the [Ca2+]i. A Ca2+-free saline significantly inhibited the Isr-induced [Ca2+]i rise. Whereas Isr in Ca2+-containing solution weakly raised the [Ca2+]i by pretreatment with thapsigargin, an inhibitor of Ca2+ release from Ca2+ stores, the Ca2+-free saline plus thapsigargin completely depressed the Isr-induced [Ca2+]i rise. The same response was observed in the case of pretreatment with cyclopiazonic acid (1 microM), another inhibitor of Ca2+ release from the Ca2+ stores. Isr raises the [Ca2+]i in Gin-1 cells and that the Isr-induced [Ca2+]i rise is ascribable to both the Ca2+ influx through the plasma membrane and Ca2+ release from the intracellular Ca2+ store.     

小檗胺对培养的HeLa细胞内游离钙浓度的作用(英文)

目的:研究Ca~(2 )信号传导是否参与Hela细胞的信号传导过程以及小檗胺(Ber)对HeLa细胞内钙浓度([Ca~(2 )]_i)变化的影响。方法:Fluo 3-AM负载HeLa细胞,共聚焦法测定[Ca~(2 )]_i,结果以荧光强度(FI)表示。结果:(1)有外钙时,HeLa细胞静息FI为186±44,KCl、NE、Cal,及咖啡因均升高HeLa细胞的[Ca~(2 )]_i。(2)Ber处理后,静息FI无影响,但抑制KCl、NE和Cal引起的[Ca~(2 )]_i升高(P<0.01),FI变化的速率减慢,达峰值的时间延长。(3)无外钙时,咖啡因诱导的[Ca~(2 )]_i升高不被Ber抑制。(4)Ber的上述作用与Ver的作用相似。结论:HeLa细胞属于非兴奋性细胞,但部分生物学特征与兴奋性细胞相似,Ca~(2 )同样在其信息转导中发挥重要作用。     

四氢吡喃类药物对血小板激活因子诱导的脑微血管平滑肌细胞DNA合成及增殖的拮抗作用

研究了血小板激活因子（ＰＡＦ）对兔血小板聚集，牛脑微血管平滑肌细胞ＤＮＡ合成及增殖的影响及四氢吡喃类药物ｔｒａｎｓ－２，６－ｂｉｓ－（３，４－ｄｉｍｅｔｈｏｘｙ－ｐｈｅｎｙｌ）－ｔｅｔｒａｈｙｄｒｏ－（４Ｈ）ｐｙｒａｎ（ＳＺ－１）和ｔｒａｎｓ－２－（３，４，５－ｔｒｉｍｅｔｈｏｘｙｐｈｅｎｙｌ）－６－（２，４－ｄｉｆｌｕｏ－ｒｏｐｈｅｎｙｌ）－ｔｅｔｒａｈｙｄｒｏ－（４Ｈ）ｐｙｒａｎ（ＤＦＴＭ）的拮抗作用．结果表明：ＰＡＦ强烈刺激兔血小板聚集，在１．９１μｍｏｌ·Ｌ－１时，刺激的百分率为７１．７％．ＳＺ－１和ＤＦＴＭ剂量依赖性地抑制ＰＡＦ刺激的兔血小板聚集，ＩＣ５０分别为０．３９和０．８４ｎｍｏｌ·Ｌ－１．ＰＡＦ还刺激牛脑微血管平滑肌细胞增殖，在０．１ｎｍｏｌ·Ｌ－１时作用４８ｈ达最大效应．ＳＺ－１和ＤＦＴＭ显著抑制血小板激活因子的上述作用，在１ｎｍｏｌ·Ｌ－１时抑制率分别为２５．９％和３０．７％．ＳＺ－１和ＤＦＴＭ还抑制ＰＡＦ刺激的牛脑微血管平滑肌细胞ＤＮＡ合成，在１ｎｍｏｌ·Ｌ－１时抑制率分别为２９．１％和２４．４％．实验结果表明：ＰＡＦ可能通过促进血小板聚集，刺激脑血管平滑肌细胞增殖及ＤＮＡ合成而参与?     

Cyclosporin A augments vasoconstrictor-induced rise in intracellular free calcium in rat renal mesangial cells

Pretreatment of rat renal mesangial cells with the immunosuppressive drug cyclosporin A caused a dose-dependent increase in the angiotensin II, [Arg8]vasopressin and noradrenalin-stimulated rise in intracellular free calcium as measured with quin 2. Cyclosporin A had no significant effect on basal cytosolic free calcium. However, cyclosporin A increased the basal 45Ca2+ influx. This stimulated 45Ca2+ influx was not blocked by nifedipine (10(-6) M). Cyclosporin A also augmented the angiotensin II, [Arg8]vasopressin and noradrenalin-stimulated efflux of 45Ca2+ from mesangial cells. These results suggest that cyclosporin A stimulates transmembrane Ca2+ influx in mesangial cells and also augments the vasoconstrictor-induced increases in cytosolic free calcium.     

内皮细胞乙酰胆碱作用靶标对胞内钙信号的调节

目的研究激活血管内皮细胞乙酰胆碱作用靶标(ETA)对不同类型血管内皮细胞[Ca2+]i水平的影响;以[Ca2+]i水平作为鉴定ETA功能的指标之一,观察其在传代过程中的改变,为研究ETA的分子结构及其信号转导途径提供实验依据.方法采用激光共聚焦技术,以荧光指示剂Fluo-3为探针,观察乙酰胆碱(ACh)和氨甲酰胆碱(carbachol,Car)对内皮细胞[Ca2+]i水平的影响.结果ACh和Car在10-5～10-2 mol*L-1可使3～10代牛主动脉内皮细胞标本的[Ca2+]i水平显著升高,ACh在 10-8～10-2 mol*L-1可使8代人冠脉内皮细胞标本的[Ca2+]i水平显著升高.结论内皮细胞在10代培养过程中外源性激动剂ACh和Car均可诱导胞内[Ca2+]i水平升高,ETA的功能与[Ca2+]i水平升高有关.     

At low extracellular calcium concentration platelet activating factor induces beta-thromboglobulin release from human platelets through thromboxane-endoperoxides formation

The aim of this study was to investigate the mechanism involved in beta-thromboglobulin (BTG) release induced by platelet activating factor (PAF) in human platelet-rich plasma (PRP) and washed platelets (WP) during aggregation. PAF was used in PRP at increasing concentrations starting at its threshold concentration for irreversible aggregation (TAC: 90-150 nM). In citrated PRP, PAF induced release of BTG (80-95% of total content) and thromboxane B2 (TXB2) formation (30-40 pmol/ml). At low PAF concentrations aggregation and BTG release were blocked by apyrase (a scavenger of ADP), by ASA (an inhibitor of cyclooxygenase) and by BM 13177 (a thromboxane receptor antagonist). Higher concentrations of PAF overcame the effect of apyrase, but only induced reversible aggregation and minor release in the presence of ASA or BM 13177. In heparinized PRP, PAF induced full irreversible aggregation, but only very low BTG release (about 25% of total content) and thromboxane synthesis (2-3 pmol/ml). WP resuspended in the presence of 2 mmol/l Ca2+ seldom responded to PAF alone, as previously shown by others, but full aggregation could be induced by concomitant addition of subthreshold concentrations of PAF (25-50 nM) and epinephrine (1 microM). In these conditions average BTG release from WP was less than 20% of the amount releasable by thrombin. In contrast, when WP were resuspended in the absence of Ca2+, stimulation by PAF + EPI induced sustained BTG release (40-50% of total content) and TXB2 synthesis (15-20 pmol/ml). We conclude that at low Ca2+ concentration PAF induces BTG release mainly through thromboxane-endoperoxides formation. In contrast, when [Ca2+] is normal, PAF does not or weakly induces thromboxane formation and BTG release.     

The effect of x-ray contrast media on the concentration of intracellular calcium in mononuclear cells

It was shown by the method of fluorescent probes that iodine-containing radiocontrast agents Triombrast > Omnipaque > Ultravist > Melitrast increase the content of intracellular Ca2+ in macrophages of the abdominal cavity of rats. Increase in the entry of Ca2+ from the external environment is the main factor of the change in the intracellular concentration of Ca2+ ions in the macrophages in interaction with radiocontrast agents.     

大鼠肺动脉平滑肌细胞培养及对不同类型激动剂刺激产生的反应

目的分离和培养SD大鼠肺动脉平滑肌细胞（PASMCc）,并检测其功能状态。方法显微分离肺内小动脉,并在含胶原酶（1750 U&#183;mL^-1）和木瓜蛋白酶（9．5U&#183;mL^-1）的低钙HBSS溶液中酶解和培养PASMCs,采用动态细胞荧光成像技术检测PASMCs胞浆游离Ca^2＋浓度（[Ca^2＋]i）的变化。结果在18～24h内可获得PASMCs,并可观察到环匹阿尼酸和5-HT可引起PASMCs[Ca^2＋]i的升高效应。结论大鼠PASMCs一步酶消化法,方法简便实用。所分离的PASMCs细胞形态和功能正常,适用于动态细胞荧光成像技术检测实验及PASMCs信号转导功能的研究。     

Antagonism of the vasodilator effects of a platelet activating factor precursor in anesthetized spontaneously hypertensive rats

The hemodynamic effects of platelet activating factor (PAF), PAF antagonists and a precursor of PAF, 1-palmityl-2-acetyl-glycerol (PAG), were examined in pentobarbital-anesthetized spontaneously hypertensive rats to determine whether functionally significant amounts of PAF are produced via the cholinephosphotransferase pathway of PAF synthesis in vivo. Intravenous bolus doses of PAF, PAG and nitroprusside elicited hypotension and active mesenteric vasodilatation. Responses to PAG were slower in onset and longer in duration than those of PAF and nitroprusside. The specific PAF antagonists, CV-3988 and SRI 63-675, attenuated PAG- and PAF-, but not nitroprusside-induced changes in blood pressure and mesenteric flow/resistance. In contrast, captopril, which blocked the effects of angiotensin I, did not influence the hypotension caused by PAG, PAF and nitroprusside. The results suggest that the vasodilator effects of PAG are attributable to PAF produced from this alkylacetylglycerol, and the renin-angiotensin system does not appear to influence the biotransformation of PAG to PAF or the hypotensive action of PAF.